Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis
- PMID: 32876694
- PMCID: PMC7489434
- DOI: 10.1001/jama.2020.17023
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis
Abstract
Importance: Effective therapies for patients with coronavirus disease 2019 (COVID-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support.
Objective: To estimate the association between administration of corticosteroids compared with usual care or placebo and 28-day all-cause mortality.
Design, setting, and participants: Prospective meta-analysis that pooled data from 7 randomized clinical trials that evaluated the efficacy of corticosteroids in 1703 critically ill patients with COVID-19. The trials were conducted in 12 countries from February 26, 2020, to June 9, 2020, and the date of final follow-up was July 6, 2020. Pooled data were aggregated from the individual trials, overall, and in predefined subgroups. Risk of bias was assessed using the Cochrane Risk of Bias Assessment Tool. Inconsistency among trial results was assessed using the I2 statistic. The primary analysis was an inverse variance-weighted fixed-effect meta-analysis of overall mortality, with the association between the intervention and mortality quantified using odds ratios (ORs). Random-effects meta-analyses also were conducted (with the Paule-Mandel estimate of heterogeneity and the Hartung-Knapp adjustment) and an inverse variance-weighted fixed-effect analysis using risk ratios.
Exposures: Patients had been randomized to receive systemic dexamethasone, hydrocortisone, or methylprednisolone (678 patients) or to receive usual care or placebo (1025 patients).
Main outcomes and measures: The primary outcome measure was all-cause mortality at 28 days after randomization. A secondary outcome was investigator-defined serious adverse events.
Results: A total of 1703 patients (median age, 60 years [interquartile range, 52-68 years]; 488 [29%] women) were included in the analysis. Risk of bias was assessed as "low" for 6 of the 7 mortality results and as "some concerns" in 1 trial because of the randomization method. Five trials reported mortality at 28 days, 1 trial at 21 days, and 1 trial at 30 days. There were 222 deaths among the 678 patients randomized to corticosteroids and 425 deaths among the 1025 patients randomized to usual care or placebo (summary OR, 0.66 [95% CI, 0.53-0.82]; P < .001 based on a fixed-effect meta-analysis). There was little inconsistency between the trial results (I2 = 15.6%; P = .31 for heterogeneity) and the summary OR was 0.70 (95% CI, 0.48-1.01; P = .053) based on the random-effects meta-analysis. The fixed-effect summary OR for the association with mortality was 0.64 (95% CI, 0.50-0.82; P < .001) for dexamethasone compared with usual care or placebo (3 trials, 1282 patients, and 527 deaths), the OR was 0.69 (95% CI, 0.43-1.12; P = .13) for hydrocortisone (3 trials, 374 patients, and 94 deaths), and the OR was 0.91 (95% CI, 0.29-2.87; P = .87) for methylprednisolone (1 trial, 47 patients, and 26 deaths). Among the 6 trials that reported serious adverse events, 64 events occurred among 354 patients randomized to corticosteroids and 80 events occurred among 342 patients randomized to usual care or placebo.
Conclusions and relevance: In this prospective meta-analysis of clinical trials of critically ill patients with COVID-19, administration of systemic corticosteroids, compared with usual care or placebo, was associated with lower 28-day all-cause mortality.
Conflict of interest statement
Figures
Comment in
-
CJEM journal club: corticosteroids use for critically ill COVID-19 patients.CJEM. 2021 Mar;23(2):162-163. doi: 10.1007/s43678-020-00056-w. Epub 2021 Jan 11. CJEM. 2021. PMID: 33709361 Free PMC article. No abstract available.
-
[Recommendations for the study and pharmacological management in adult patients with suspected infection by SARS-CoV-2 (COVID-19)].Rev Chilena Infectol. 2020 Dec;37(6):646-666. doi: 10.4067/S0716-10182020000600646. Rev Chilena Infectol. 2020. PMID: 33844805 Spanish. No abstract available.
Similar articles
-
Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials.Trials. 2020 Aug 24;21(1):734. doi: 10.1186/s13063-020-04641-3. Trials. 2020. PMID: 32831155 Free PMC article.
-
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.JAMA. 2021 Aug 10;326(6):499-518. doi: 10.1001/jama.2021.11330. JAMA. 2021. PMID: 34228774 Free PMC article.
-
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9. Trials. 2020. PMID: 33115543 Free PMC article.
-
Low-Dose Corticosteroids for Critically Ill Adults With Severe Pulmonary Infections: A Review.JAMA. 2024 Jul 23;332(4):318-328. doi: 10.1001/jama.2024.6096. JAMA. 2024. PMID: 38865154 Review.
-
Systemic corticosteroids for the treatment of COVID-19: Equity-related analyses and update on evidence.Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD014963. doi: 10.1002/14651858.CD014963.pub2. Cochrane Database Syst Rev. 2022. PMID: 36385229 Free PMC article. Review.
Cited by
-
Retrospective Comparison of Influenza and COVID-19-Associated Acute Respiratory Distress Syndrome (ARDS): An Experience From a Tertiary Care Hospital.Cureus. 2024 Aug 11;16(8):e66636. doi: 10.7759/cureus.66636. eCollection 2024 Aug. Cureus. 2024. PMID: 39258093 Free PMC article.
-
The usage of immunosuppressant agents and secondary infections in patients with COVID-19 in the intensive care unit: a retrospective study.Sci Rep. 2024 Sep 9;14(1):20991. doi: 10.1038/s41598-024-71912-3. Sci Rep. 2024. PMID: 39251824 Free PMC article.
-
Revisiting the COVID-19 Pandemic: Mortality and Predictors of Death in Adult Patients in the Intensive Care Unit.Life (Basel). 2024 Aug 19;14(8):1027. doi: 10.3390/life14081027. Life (Basel). 2024. PMID: 39202769 Free PMC article.
-
Evaluating the Risk-Benefit Profile of Corticosteroid Therapy for COVID-19 Patients: A Scoping Review.Pharmacy (Basel). 2024 Aug 22;12(4):129. doi: 10.3390/pharmacy12040129. Pharmacy (Basel). 2024. PMID: 39195858 Free PMC article. Review.
-
Outcomes of different steroid dosing regimens in critical Covid-19 pneumonia at a Kenyan hospital: A retrospective cohort study.PLoS One. 2024 Aug 20;19(8):e0307265. doi: 10.1371/journal.pone.0307265. eCollection 2024. PLoS One. 2024. PMID: 39163391 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
- MC_PC_19056/MRC_/Medical Research Council/United Kingdom
- MC_UU_00017/3/MRC_/Medical Research Council/United Kingdom
- MC_U137686861/MRC_/Medical Research Council/United Kingdom
- MC_PC_18033/MRC_/Medical Research Council/United Kingdom
- 001/WHO_/World Health Organization/International
- MC_UU_12023/22/MRC_/Medical Research Council/United Kingdom
- MC_PC_20062/MRC_/Medical Research Council/United Kingdom
- MC_UU_12023/21/MRC_/Medical Research Council/United Kingdom
- RP-2015-06-018/DH_/Department of Health/United Kingdom
- MC_U137686860/MRC_/Medical Research Council/United Kingdom
- MC_UU_12026/4/MRC_/Medical Research Council/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical